Prescribed courses of treatment in accordance with these recommendations will only be effective if they are followed.\n Jude Medical None None None Smadar Kort Content Reviewer: ACCF Echocardiography ...Committee None Bristol-Myers Squibb None Philips None None None Harlan Krumholz Content Reviewer: ACC/AHA Task Force on Practice Guidelines None None None None None None None Fred Kushner Content Reviewer: ACC/AHA Task Force on Practice Guidelines None CV Therapeutics; Novartis None None None Pfizer; Sanofi-Aventis None Jerrold Levy Content Reviewer: AHA Council on Cardiovascular Surgery and Anesthesia Leadership Committee Alexion Pharmaceuticals, Inc; Dianon Systems PDL BioPharma None Abbott Laboratories; Alexion Pharmaceuticals, Inc; The Medicines Co; Novo Nordisk Council on Clinical Cardiology Leadership Committee None None None None None None None Jay Silverstein Content Reviewer: ACCF Cardiovascular Imaging Committee None None None None None None None Kim Williams Content Reviewer: ACCF Cardiovascular Clinical Imaging Committee CV Therapeutics*; GE Healthcare*; King Pharmaceuticals, Inc* Astellas Healthcare*; GE Healthcare* None Bristol-Myers Squibb*; CV Therapeutics*; GE Healthcare*; Molecular Insight Pharmaceuticals, Inc* None None None Stuart Winston Content Reviewer: AHA Clinical Electrophysiology Committee Boston Scientific/Guidant None None Biotronik; Boston Scientific/Guidant; Medtronic None None None Janet Wyman Content Reviewer: ACCF Cardiac Catheterization Committee None None None None None None None Appendix II Peer Revieer Relationships With Industry: ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery This table represents the relationships of peer reviewers with industry that were disclosed at the time of peer review of this guideline. Abbreviation Definition ACC American College of Cardiology ACS American College of Surgeons ADA American Diabetes Association AHA American Heart Association CAD coronary artery disease CARP Coronary Artery Revascularization Prophylaxis DECREASE Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography ECG electrocardiogram ICD implantable cardioverter-defibrillator LV left ventricle/left ventricular MET metabolic equivalent MI myocardial infarction PCI percutaneous coronary intervention SCAI Society for Cardiovascular Angiography and Interventions Appendix III Abbreviations List
Bare-metal stents have been replaced by drug-eluting stents in the majority of cases, which further reduce the risk of restenosis (3). Because stents or other interventional devices are commonly ...used, the coronary angioplasty procedure is more aptly termed "percutaneous coronary intervention" (PCI). ...of the maturation of PCI as a discipline and the ongoing clarification of its role in the management of coronary heart disease, the public can and should appropriately expect consistent access to high-quality PCI capability. Recognition and management of complications are critical components of PCI procedures that require skill, knowledge, experience, and judgment. Since there can be variation among operators in cognitive knowledge and skill and among procedures in technical difficulty, there is a potential for substantial variation in procedure safety and efficacy.\n Robert O. Bonow *Content-PCI Guideline Writing Committee None None None None None None None Dr. Jose G. Diez *Content-ACCF Cardiac Catheterization and Intervention Committee None None None None None None None Dr. Ted E. Feldman *Content-ACCF Cardiac Catheterization and Intervention Committee *Boston Scientific *Cardiac Dimensions *Cordis *Myocor *Abbott *Atritech *Boston Scientific *Cardiac Dimensions *Cordis *Evalve None None None None None Dr. James Ferguson *Content-Individual Reviewer None None None None None None None Dr. Tommaso Gori *Content-AHA Diagnostic & Interventional Cardiac Catherization Committee None None None None None None None Dr. Hani Jneid *Content-AHA Diagnostic & Interventional Cardiac Catheterization Committee None Pfizer None None None None None Dr. Fred M. Krainin *Content-ACCF Cardiac Catheterization and Intervention Committee None None None None None *Boston Scientific *Johnson & Johnson *Medtronic None Dr. Glenn Levine *Content-AHA Diagnostic & Interventional Cardiac Catheterization Committee None None None None None None None Dr. Charanjit S. Rihal *Content-ACCF Cardiac Catheterization and Intervention Committee None None None None None None None Dr. Dan M. Roden *Content-Individual Reviewer *Abbott *Alza *Arpida *AstraZeneca *Bristol-Myers Squibb *CV Therapeutics *EBR Systems *First Genetic Trust *GlaxoSmithKline *Genzyme *Johnson & Johnson *Lexicon *Lundbeck *Medtronic *Merck *NPS Pharmaceuticals *Novartis *Pfizer *Sanofi-Synthelabo Groupe *Solvay *Thornton Medical *Wyeth *Yamanouchi None None None None None None Dr. Carlos Ruiz *Content-ACCF Cardiac Catheterization and Intervention Committee None None None None None None None Dr. Michael J. Silka *Content-Individual Reviewer None None None None None None *General Electric Dr. Thoralf M. Sundt *Content-ACCF Cardiac Catheterization and Intervention Committee None None None None None *Medtronic (son has stock) None Dr. Cynthia M. Tracy *Content-Individual Reviewer None *Guidant Corp *Medtronic None None None None None Dr. E. Murat Tuzcu *Content-AHA Diagnostic & Interventional Cardiac Catheterization Committee None None None None None None None Dr. Matthew Wolff *Content-ACCF Cardiac Catheterization and Intervention Committee None None None None None None None Dr. Yerem Yeghazarans *Content-Individual Reviewer None None None *Pfizer *Sanofi-Aventis None None None Table 4 Key Components of a Quality Assurance Program Author Relationships With Industry--ACCF/AHA/SCAI Writing Committee to Update the Clinical Competence Statement on Cardiac Interventional Procedures This table represents the relationships of committee members with industry that were reported orally at the initial writing committee meeting and updated in conjunction with all meetings and conference calls of the writing committee during the document development process.
This paper will report on the work performed by BP Solar during the first two years of NREL PVMaT subcontract #ZDO-2-30628-03. The major objectives of this program are to continue the advancement of ...BP Solar's multicrystalline silicon manufacturing technology to: increase ingot size; improve ingot material quality; develop wire saws to slice 100 /spl mu/m thick silicon wafers; develop equipment for demounting and handling of ultra-thin wafers; develop cell processes that produce cells with efficiencies of at least 15.4% at an overall yield exceeding 95%; expand existing in-line manufacturing data reporting systems; establish a 50 MW factory model; and facilitate an increase in the silicon feedstock industry's production capacity for lower-cost solar grade feedstock.
PDF
